On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q1 2023 earnings per share (EPS) of -$0.14, up 60% year over year. Total Akebia Therapeutics earnings for the quarter were -$26.22 million. In the same quarter last year, Akebia Therapeutics's earnings per share (EPS) was -$0.35.
As of Q2 2023, Akebia Therapeutics's earnings has grown year over year. Akebia Therapeutics's earnings in the past year totalled -$56.36 million.
What was AKBA's revenue last quarter?
On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q1 2023 revenue of $40.13 million up 34.96% year over year. In the same quarter last year, Akebia Therapeutics's revenue was $61.70 million.
What was AKBA's revenue growth in the past year?
As of Q2 2023, Akebia Therapeutics's revenue has grown 21.55% year over year. This is 47.66 percentage points lower than the US Biotechnology industry revenue growth rate of 69.21%. Akebia Therapeutics's revenue in the past year totalled $271.03 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.